Studi clinici su Obesità nello stato di Pennsylvania
48 studi su Obesità cercano partecipanti presso sedi nello stato di Pennsylvania.
Città nello stato di Pennsylvania
Testo ufficiale dello studio (inglese)
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Suburban Research Associates, West Chester
- Cardiology Consultants of Philadelphia Yardley, Yardley
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT07783802A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
- Heritage Valley Medical Group, Beaver
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT07564414A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- UPMC Child Hosp-Pittsburgh, Pittsburgh
In reclutamentoFase 3
Età da 8 a 18 · Tutti i sessi · Aggiornato il 30 set 2026 · NCT07253285A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- Geisinger Clinic, Danville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07668414A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Smithfield
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07776509Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
- Penn State Milton S. Hershey Medical Center, Hershey
In reclutamentoFase 1 iniziale
Età da 18 a 65 · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06482853Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Thomas Jefferson University - Medicine/GI and Hepatology, Philadelphia
In reclutamentoFase 3
Età da 18 a 70 · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06937099A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- UPMC Children's Hospital of Pittsburgh, Pittsburgh
In reclutamentoFase 3
Età da 6 a 17 · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06672549Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Thomas Jefferson University - Medicine/GI and Hepatology, Philadelphia
In reclutamentoFase 3
Età da 18 a 70 · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06937086AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
- UPA Ctr Weight and Eating Dis, Philadelphia
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 set 2026 · NCT07339423A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair, Pittsburgh
- Preferred Primary Care Physicians, Uniontown
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07282600A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18), Pittsburgh
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07392190A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Scottdale
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07784270Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Heritage Valley Multispecialty Group Inc, Beaver
- Capital Area Research LLC, Camp Hill
- Abington Medical Specialists, Horsham
In reclutamentoFase 3
Età da 45 a 99 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Preferred Primary Care Physicians, Uniontown
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07321886Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Keystone Clinical Studies, Plymouth Meeting
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07353931A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Philadelphia
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Philadelphia
- AURORA-2 Clinical Site, Pittsburgh
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT07743450Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- Abington Medical Specialists, Horsham
- University of Pittsburgh Medical Center, Pittsburgh
In reclutamentoFase 3
Età da 18 a 99 · Tutti i sessi · Aggiornato il 16 set 2026 · NCT07037459A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- VA Pittsburgh Healthcare System, Pittsburgh
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Frontier Clinical Research, LLC, Scottdale
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 14 set 2026 · NCT06897475A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Suburban Research Associates - West Chester Office, West Chester
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT07351045AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
- Clinical Research Associates of Central PA, LLC, DuBois
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 set 2026 · NCT07571005A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Philadelphia
In reclutamentoFase 3Volontari sani benvenuti
Età da 18 a 79 · Tutti i sessi · Aggiornato il 11 set 2026 · NCT07654374Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
- UPA Ctr Weight and Eating Dis, Philadelphia
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT07770841AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
- Clinical Research Associates of Central PA, LLC, DuBois
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT07571109A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Dermatology Associates of Plymouth Meeting, Plymouth Meeting
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT06857942Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Capital Area Research LLC, Newport
In reclutamentoFase 3
Età da 18 a 99 · Tutti i sessi · Aggiornato il 3 set 2026 · NCT07684235Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Altoona Center for Clinical Research, Duncansville
In reclutamentoFase 3
Età da 18 a 99 · Tutti i sessi · Aggiornato il 27 ago 2026 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Philadelphia
- Research Site, Smithfield
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT07784725Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Children's Hospital of Philadelphia, Philadelphia
In reclutamentoFase 2
Età da 7 a 25 · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT05082519A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- Penn State Hlth Holy Spirit Med Ctr, Camp Hill
- Chambersburg Hospital, Chambersburg
- Doylestown Heath cardiology, Doylestown
- e altri 2
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 ago 2026 · NCT07567001Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Philadelphia
In reclutamentoFase 3
Età da 18 a 79 · Tutti i sessi · Aggiornato il 10 ago 2026 · NCT07654361Fast In-Bed Tracking (FIT) System Lifestyle Intervention is a Clinical Trial of a Bed Scale Device. Overweight Wheelchair Users Will Complete a Weight Loss Program, Half Get Scales at Baseline, Half at Month 6 Those Who Receive the Bed Scales at Baseline Are Expected to Have Increased Weight Loss
- University of Pittsburgh, Bakery Square, Department of Rehabilitation Science and Technology, Pittsburgh
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 lug 2026 · NCT07141342Pharmacogenetics of Response to GLP1R Agonists
- Amish Research Clinic, Lancaster
In reclutamentoFase 1Volontari sani benvenuti
Età da 18 a 89 · Tutti i sessi · Aggiornato il 27 lug 2026 · NCT05071898A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
- Altoona Center for Clinical Research, Duncansville
In reclutamentoFase 2
Età da 18 a 80 · Tutti i sessi · Aggiornato il 22 lug 2026 · NCT07477704An Acceptance-Based Healthy Lifestyle Intervention for Diverse Adolescents
- Drexel University, Philadelphia
In reclutamentoVolontari sani benvenuti
Età da 14 a 19 · Donne · Aggiornato il 20 lug 2026 · NCT06147973Weight Bias Reducation Intervention With Nursing Students Using Simulation: The BRAVE Study
- Villanova University, Villanova
In reclutamento
Età da 18 a 35 · Tutti i sessi · Aggiornato il 17 lug 2026 · NCT07334470Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
- University of Pittsburgh, Pittsburgh
In reclutamento
Età da 18 a 45 · Donne · Aggiornato il 24 giu 2026 · NCT05124808The Effects of Strength Training on Muscle Mass and Mental Health in Adults Taking Obesity Medication
- Physical Activity Research Center, University of Pittsburgh, Pittsburgh
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 giu 2026 · NCT07652333Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.